Biogen Collaborates with Stoke Therapeutics to Develop and Commercialize Zorevunersen for Dravet Syndrome
Shots:
- Biogen & Stoke have partnered to develop & market zorevunersen for Dravet syndrome with Stoke retaining rights in the US, Canada, & Mexico while leading global development & Biogen securing marketing rights in other regions
- As per the deal, Stoke will get $165M upfront, ~$385M in development & commercial milestones, & net sales-based tiered royalties, where external development will be co-funded (30% Biogen, 70% Stoke). Also, Biogen has an option to license certain future follow-on SCN1A-targeting ASOs with separate terms in its licensed regions
- Stoke plans to initiate global P-III (EMPEROR) trial of zorevunersen in Q2’25 with readout expected in H2’27 which will potentially support regulatory filings worldwide
Ref: Biogen | Image: Biogen & Stoke Therapeutics
Related News:- Royalty Pharma Partners with Biogen to Develop Litifilimab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
